

DAFTAR PUSTAKA

- Ades, P.A. and Savage, P.D. (2017) "Obesity in coronary heart disease: An unaddressed behavioral risk factor," *Preventive Medicine*, 104, pp. 117–119. doi:10.1016/j.ypmed.2017.04.013.
- Ahmed, A.N. *et al.* (2015) "Assesment of Coronary Artery Disease by The Detection of Inflammatory Marker Like Erythrocyte Sedimentation Rate, Neutrophil Lymphocyte Ratio and Leucocyte Count," *University Heart Journal*, 10(2), pp. 55–59. doi:10.3329/uhj.v10i2.26121.
- Akın, F. *et al.* (2015) "Predictors of poor coronary collateral development in patients with stable coronary artery disease: Neutrophil-to-lymphocyte ratio and platelets," *Anadolu Kardiyoloji Dergisi*, 15(3), pp. 218–223. doi:10.5152/akd.2014.5263.
- Alhadj, M. and Babos, M. (2019) *Physiology, Salivation, StatPearls*. StatPearls Publishing.
- De Almeida, P.D.V. *et al.* (2008) "Saliva composition and functions: A comprehensive review," *Journal of Contemporary Dental Practice*, 9(3), pp. 072–080. doi:10.5005/jcdp-9-3-72.
- Alvitigala, B.Y. *et al.* (2018) "A study of association between platelet volume indices and ST elevation myocardial infarction," *IJC Heart and Vasculature*, 21, pp. 7–10. doi:10.1016/j.ijcha.2018.09.001.
- Ambari, A.M. (2017) "Faktor Risiko dan Pencegahan Primer Penyakit Kardiovaskular," in Yuniadi, Y., Hermanto, D.Y., and Siswanto, B.B. (eds) *Buku Ajar Kardiovaskular Jilid 2*. Jakarta: CV Sagung Seto, pp. 45–67.
- Ambrose, J.A. and Singh, M. (2015) *Pathophysiology of Coronary Artery Disease Leading to Acute Coronary Syndromes, F1000Prime Reports*. doi:10.12703/p7-08.
- American Diabetes Association (2016) "Cardiovascular Disease and Risk Management," *Diabetes Care*, 39(Supplement 1), pp. S60–S71. doi:10.2337/dc16-S011.
- American Heart Association (2015) "Coronary Artery Disease - Coronary Heart Disease | American Heart Association," *Heart.org* [Preprint].
- American Heart Association (2019) *Coronary Heart Disease, Heart and Stroke Encyclopedia*. Available at: http://www.heart.org/HEARTORG/Encyclopedia/Heart-Encyclopedia_UCM_445084_Encyclopedia.jsp?levelSelected=&title=coronary heart disease.
- Angkananard, T. *et al.* (2018) "Neutrophil Lymphocyte Ratio and Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis," *BioMed Research International*. Hindawi Limited. doi:10.1155/2018/2703518.
- Bacchioga, B.C. *et al.* (2017) "Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study," *Journal of the American Heart Association*, 6(3). doi:10.1161/JAHA.116.005038.

- Balta, S. *et al.* (2016) "The Relation between Atherosclerosis and the Neutrophil-Lymphocyte Ratio," *Clinical and Applied Thrombosis/Hemostasis*, 22(5), pp. 405–411. doi:10.1177/1076029615569568.
- Barengo, N.C. *et al.* (2017) "Coronary heart disease incidence and mortality, and all-cause mortality among diabetic and non-diabetic people according to their smoking behavior in Finland," *Tobacco Induced Diseases*, 15(1), pp. 1–8. doi:10.1186/s12971-017-0113-3.
- Bobryshev, Y. v. *et al.* (2016) "Macrophages and Their Role in Atherosclerosis: Pathophysiology and Transcriptome Analysis," *BioMed Research International*, 2016(Figure 1), pp. 1–13. doi:10.1155/2016/9582430.
- Bosch, J.A. (2014) "The use of saliva markers in psychobiology: Mechanisms and methods," *Monographs in Oral Science*, 24, pp. 99–108. doi:10.1159/000358864.
- Caselli, C. *et al.* (2015) "HDL Cholesterol, Leptin and Interleukin-6 Predict High Risk Coronary Anatomy Assessed by CT Angiography in Patients with Stable Chest Pain," *Atherosclerosis*. Elsevier Ltd, pp. 55–61. doi:10.1016/j.atherosclerosis.2015.04.811.
- Chen, H. *et al.* (2019) "Monocyte/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients with non-ST-elevation myocardial infarction," *Medicine*, 98(26). doi:10.1097/MD.00000000000016267.
- Cheng, H.-R. *et al.* (2020) "High Monocyte-To-Lymphocyte Ratio Is Associated With Stroke-Associated Pneumonia," *Frontiers in Neurology*, 11. doi:10.3389/fneur.2020.575809.
- Chistiakov, D.A., Orekhov, A.N. and Bobryshev, Y. V. (2015) "Endothelial barrier and its abnormalities in cardiovascular disease," *Frontiers in Physiology*, 6(DEC), pp. 1–11. doi:10.3389/fphys.2015.00365.
- Christoffersen, M. and Tybjaerg-Hansen, A. (2021) "Targeting IL-6 in patients at high cardiovascular risk," *The Lancet*, 397(10289). doi:10.1016/S0140-6736(21)00985-5.
- Cui, C.J. *et al.* (2018) "Tissue Factor-bearing MPs and The Risk of Venous Thrombosis in Cancer Patients: A Meta-analysis," *Scientific Reports*, 8(1). doi:10.1038/s41598-018-19889-8.
- Daniel I Swerdlow *et al.* (2012) "The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis," *The Lancet*, 379(9822). doi:10.1016/S0140-6736(12)60110-X.
- Dans, A. *et al.* (2011) "The Rise of Chronic Non-Communicable Diseases in Southeast Asia: Time for Action," *The Lancet*, 377(9766), pp. 680–689. doi:10.1016/S0140-6736(10)61506-1.
- Dekker, R.L. *et al.* (2016) "Salivary Biomarkers, Oral Inflammation, and Functional Status in Patients With Heart Failure," *Biological Research For Nursing*, 19(2), pp. 153–161. doi:10.1177/1099800416665197.
- Dobrucka-głowacka, A. *et al.* (2018) "Interleukin-6 in Cardiovascular Disorders," *European Journal of Medical Technologies*, 3(20), pp. 23–30.

- Doran, A.C., Meller, N. and McNamara, C.A. (2008) "Role of Smooth Muscle Cells in the Initiation and Early Progression of Atherosclerosis," *Arteriosclerosis, Thrombosis, and Vascular Biology*, 28(5). doi:10.1161/ATVBAHA.107.159327.
- E, L. *et al.* (2010) "Increased Levels of Proinflammatory Cytokines in Children with Family History of Coronary Artery Disease," *Clinical Cardiology* [Preprint]. doi:10.1002/clc.20434.
- Faiz, O. and Moffat, D. (2002) *Anatomy at A Glance*. USA: Blackwell Science Ltd.
- Farkas, J. (2019) *PulmCrit: Neutrophil-Lymphocyte Ratio (NLR): Free upgrade to your WBC*. Available at: <https://emcrit.org/pulmcrit/nlr/> (Accessed: September 29, 2021).
- Ference, B.A. *et al.* (2017) "Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from The European Atherosclerosis Society Consensus Panel," *European Heart Journal*, 38, pp. 2459–2472. doi:10.1093/eurheartj/ehx144.
- Fernandez, D.M. and Giannarelli, C. (2021) "Immune cell profiling in atherosclerosis: role in research and precision medicine," *Nature Reviews Cardiology* [Preprint]. doi:10.1038/s41569-021-00589-2.
- Fisman, E.Z. *et al.* (2006) "Interleukin-6 and the Risk of Future Cardiovascular Events in Patients With Angina Pectoris and/or Healed Myocardial Infarction," *The American Journal of Cardiology*, 98(1). doi:10.1016/j.amjcard.2006.01.045.
- Fontes, J.A., Rose, N.R. and Čiháková, D. (2015) "The Varying Faces of IL-6: From Cardiac Protection to Cardiac Failure," *Cytokine*. Elsevier Ltd. doi:10.1016/j.cyto.2014.12.024.
- GA Wells *et al.* (no date) *The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses*, Ottawa Hospital Research Institute. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed: July 5, 2021).
- Gerin, F. *et al.* (2017) "Relation of Interleukin-6 Level with Coronary Artery Disease Severity in Patients Undergoing Coronary Angiography," *European Journal of Therapeutics*, 23(3), pp. 117–121. doi:10.5152/eurjther.2017.01007.
- Gregersen, I. and Halvorsen, B. (2016) "Atherosclerosis - Yesterday, Today and Tomorrow," *Intech*, i(tourism), p. 13. doi:http://dx.doi.org/10.5772/57353.
- Gu, Q. *et al.* (2019) "The Link Between Hematopoiesis and Atherosclerosis," 363(6431), pp. 1085–1088. doi:10.1126/science.aav1749.AIBP-mediated.
- Guyton, A.C. and Hall, J.E. (2016) *Buku Ajar Fisiologi Kedokteran*. 12th edn. Indonesia: Elsevier Ltd.
- Hackshaw, A. *et al.* (2018) "Low cigarette consumption and risk of coronary heart disease and stroke: Meta-analysis of 141 cohort studies in 55 study reports," *BMJ (Online)*, 360. doi:10.1136/bmj.j5855.

- Hajar, R. (2017) "Risk Factors for Coronary Artery Disease: Historical Perspectives," *Heart Views: The Official Journal of the Gulf Heart Association*, 18(3), p. 109. doi:10.4103/HEARTVIEWS.HEARTVIEWS_106_17.
- Hartman, J. and Frishman, W.H. (2014) "Inflammation and Atherosclerosis," *Cardiology in Review*, 22(3). doi:10.1097/CRD.0000000000000021.
- Haybar, H. et al. (2016) "Intermediate-risk Chronic Stable Angina: Neutrophil-Lymphocyte Ratio and Fibrinogen Levels Improved Predicting Angiographically-detected Coronary Artery Disease," *Iranian Red Crescent Medical Journal*, 18(9). doi:10.5812/ircmj.18570.
- Higgins JPT et al. (2021) *Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)*, Cochrane. Available at: www.training.cochrane.org/handbook (Accessed: June 5, 2021).
- Ilhan, F. (2015) "Atherosclerosis and the role of immune cells," *World Journal of Clinical Cases*, 3(4). doi:10.12998/wjcc.v3.i4.345.
- Jagannathan-Bogdan, M. and Zon, L.I. (2013) "Hematopoiesis," *Development (Cambridge, England)*, 140(12), pp. 2463–7. doi:10.1242/dev.083147.
- Javaid, M.A. et al. (2016) "Saliva as A Diagnostic Tool for Oral and Systemic Diseases," *Journal of Oral Biology and Craniofacial Research*, 6(1), pp. 67–76. doi:10.1016/j.jobcr.2015.08.006.
- Ji, H. et al. (2017) "Monocyte/Lymphocyte Ratio Predicts the Severity of Coronary Artery Disease: A Syntax Score Assessment," *BMC Cardiovascular Disorders*, 17(1). doi:10.1186/s12872-017-0507-4.
- Jiang, P. et al. (2015) "Significance of eosinophil accumulation in the thrombus and decrease in peripheral blood in patients with acute coronary syndrome," *Coronary Artery Disease*, 26(2). doi:10.1097/MCA.000000000000186.
- Jousilahti, P. et al. (1999) "Sex, Age, Cardiovascular Risk Factors, and Coronary Heart Disease," *Circulation*, 99(9). doi:10.1161/01.CIR.99.9.1165.
- Kabo, P. (2010) *Bagaimana Menggunakan Obat-Obat Kardiovaskular secara Rasional*. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia.
- Kaptoge, S. et al. (2014) "Inflammatory Cytokines and Risk of Coronary Heart Disease: New Prospective Study and Updated Meta-Analysis," *European Heart Journal*, 35(9), pp. 578–589. doi:10.1093/eurheartj/eh367.
- Kawahara, R. and Shiozawa, Y. (2015) "Hematopoiesis ☆ Methods to Study Hematopoiesis Hematopoietic Stem Cell Markers Hematopoiesis During Development," *Elsevier Inc.*, (December 2014), pp. 1–4. doi:10.1016/B978-0-12-801238-3.05054-6.
- Kemendes RI (2018) *Hasil Utama Riset Kesehatan Dasar 2018*, Kementerian Kesehatan RI: Badan Penelitian dan Pengembangan Kesehatan. Indonesia.
- Kishimoto, T. et al. (2014) "Encyclopedia of Inflammatory Diseases," *Encyclopedia of Inflammatory Diseases*. Springer Basel. doi:10.1007/978-3-0348-0620-6.

- Konishi, T. *et al.* (2017) "Prognostic Value of Eosinophil to Leukocyte Ratio in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention," *Journal of Atherosclerosis and Thrombosis*, 24(8). doi:10.5551/jat.37937.
- Kosaka, T. *et al.* (2014) "Salivary Inflammatory Cytokines May be Novel Markers of Carotid Atherosclerosis in A Japanese General Population: The Suita Study," *Atherosclerosis*, 237(1), pp. 123–128. doi:10.1016/j.atherosclerosis.2014.08.046.
- Kounis, N.G. *et al.* (2015) "White blood cell counts, leukocyte ratios, and eosinophils as inflammatory markers in patients with coronary artery disease," *Clinical and Applied Thrombosis/Hemostasis*, 21(2), pp. 139–143. doi:10.1177/1076029614531449.
- Kumar, V., Abbas, A.K. and Aster, J.C. (2018) "Robbins Basic Pathology, Tenth Edition." Elsevier Inc.
- Kurtul, A. and Ornek, E. (2019) "Platelet to Lymphocyte Ratio in Cardiovascular Diseases: A Systematic Review," *Angiology*, 70(9). doi:10.1177/0003319719845186.
- Kusmana, D. and Hanafi, M. (2004) "Patofisiologi Penyakit Jantung Koroner," in Rilantono, L. (ed.) *Buku Ajar Kardiologi*. Jakarta: Balai Penerbit Fakultas Kedokteran Universitas Indonesia.
- Lavie, C.J. *et al.* (2014) "Obesity and cardiovascular diseases: Implications regarding fitness, fatness, and severity in the obesity paradox," *Journal of the American College of Cardiology*, 63(14), pp. 1345–1354. doi:10.1016/j.jacc.2014.01.022.
- Lee, J.M., Garon, E.B. and Wong, D.T. (2019) "Salivary Diagnostics," *Saliva [Working Title]*, (February), pp. 206–211. doi:10.5772/intechopen.84722.
- Levine, G.N. *et al.* (2011) "2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions," *Circulation*, 124(23). doi:10.1161/CIR.0b013e31823ba622.
- Li, X.T. *et al.* (2020) "Association of Platelet to Lymphocyte Ratio with In-Hospital Major Adverse Cardiovascular Events and the Severity of Coronary Artery Disease Assessed by the Gensini Score in Patients with Acute Myocardial Infarction," *Chinese Medical Journal*, 133(4), pp. 415–423. doi:10.1097/CM9.0000000000000650.
- Lilly, L.S. (2011) *Pathophysiology of Heart Disease: A Collaborative Project of Medical Students and Faculty*. 5th edn.
- Lima, D.P. *et al.* (2010) "Saliva: reflection of the body," *International Journal of Infectious Diseases*, 14(3), pp. e184–e188. doi:10.1016/J.IJID.2009.04.022.
- Low Wang, C.C. *et al.* (2016) "Clinical update: Cardiovascular disease in diabetes mellitus," *Circulation*, 133(24), pp. 2459–2502. doi:10.1161/CIRCULATIONAHA.116.022194.

- Luijendijk, H.J. (2021) "How to create PICO questions about diagnostic tests," *BMJ Evidence-Based Medicine*, p. bmjebm-2021-111676. doi:10.1136/bmjebm-2021-111676.
- Madjid, M. and Fatemi, O. (2013) "Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update.," *Texas Heart Institute journal*, 40(1), pp. 17–29. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23467296> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3568280>.
- Maguire, E.M., Pearce, S.W.A. and Xiao, Q. (2019) "Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease," *Vascular Pharmacology*, 112(July 2018), pp. 54–71. doi:10.1016/j.vph.2018.08.002.
- Marx, C. *et al.* (2019) "Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps," *Blood*, 134(21). doi:10.1182/blood.2019000518.
- Miller, C.S. *et al.* (2010) "Current developments in salivary diagnostics," *Biomarkers in Medicine*, pp. 171–189. doi:10.2217/bmm.09.68.
- Min, X. *et al.* (2017) "Serum Cytokine Profile in Relation to the Severity of Coronary Artery Disease," *BioMed Research International*, 2017. doi:10.1155/2017/4013685.
- Muliana, M., Rahmat, B. and Priyambodo, S. (2020) "The Correlation between Lymphocyte Platelet Ratio and Gensini Score in Coronary Heart Disease Patients," *Mutiara Medika: Jurnal Kedokteran dan Kesehatan*, 20(1). doi:10.18196/mm.200136.
- Mundi, S. *et al.* (2018) "Endothelial permeability, LDL deposition, and cardiovascular risk factors-A review," *Cardiovascular Research*, 114(1), pp. 35–52. doi:10.1093/cvr/cvx226.
- N Kose *et al.* (2019) "The Association Between the Lymphocyte-to-Monocyte Ratio and Coronary Artery Disease Severity in Patients With Stable Coronary Artery Disease," *European Review for Medical and Pharmacological Sciences*, 23(6), pp. 2570–2575. doi:10.26355/eurrev_201903_17406.
- Nadimi, A.E., Ahmadi, J. and Mehrabian, M. (2008) "Peripheral eosinophil count and allergy in patients with coronary artery disease.," *Acta medica Indonesiana*, 40(2).
- Navazesh, M. and Kumar, S.K.S. (2008) "Measuring salivary flow," *The Journal of the American Dental Association*, 139(May), pp. 35S-40S. doi:10.14219/jada.archive.2008.0353.
- Ni, J. *et al.* (2019) "Neutrophil to lymphocyte ratio (NLR) as a prognostic marker for in-hospital mortality of patients with sepsis," *Medicine*, 98(46). doi:10.1097/MD.00000000000018029.
- Niccoli, G. and Cosentino, N. (2012) "Eosinophils: a new player in coronary atherosclerotic disease," *Hypertension Research*, 35(3). doi:10.1038/hr.2011.221.
- NIH (2019) *Ischemic Heart Disease, National Health, Lung, and Blood Institute*. Available at: <https://www.nhlbi.nih.gov/health-topics/ischemic-heart-disease> (Accessed: May 15, 2019).

- Nording, H.M., Seizer, P. and Langer, H.F. (2015) "Platelets in Inflammation and Atherogenesis," *Frontiers in Immunology*, 6. doi:10.3389/fimmu.2015.00098.
- Nunez, J. *et al.* (2011) "Low Lymphocyte Count and Cardiovascular Diseases," *Current Medicinal Chemistry*, 18(21). doi:10.2174/092986711796391633.
- O'Donnell, C.J. and Elosua, R. (2008) "Cardiovascular risk factors. Insights from framingham heart study," *Revista Espanola de Cardiologia*, 61(3), pp. 299–310. doi:10.1157/13116658.
- PAPDI (2015) *Penatalaksanaan di Bidang Ilmu Penyakit Dalam: Panduan Praktik Klinis*. Edited by I. Alwi *et al.* Jakarta: Interna Publishing.
- PERKI (2018) "Pedoman Laboratorium Kateterisasi Jantung dan Pembuluh Darah," p. 60.
- Pfaffe, T. *et al.* (2011) "Diagnostic Potential of Saliva: Current state and future applications," *Clinical Chemistry*, 57(5), pp. 675–687. doi:10.1373/clinchem.2010.153767.
- Punj, A. (2018) "Secretion of Human Salivary Glands," in Paridah, M. *t et al.* (eds) *Salivary Glands: New Approach in Diagnostics and Treatment*. Licensee IntechOpen, p. 13. doi:http://dx.doi.org/10.5772/57353.
- Rahman, O.J. and Yugo, D. (2017) "Aliran Darah Koroner dan Iskemia Miokard," in Yuniadi, Y., Hermanto, D.Y., and Siswanto, B.B. (eds) *Buku Ajar Kardiovaskular Jilid 2*. Jakarta: CV Sagung Seto, pp. 131–41.
- Rathnayake, N. *et al.* (2013) "Salivary Biomarkers for Detection of Systemic Diseases," *Plos One*, 8(4). doi:10.1371/journal.pone.0061356.
- Realyvásquez-Vargas, A. *et al.* (2020) "The Impact of Environmental Factors on Academic Performance of University Students Taking Online Classes During the COVID-19 Pandemic in Mexico," *Sustainability (Switzerland)*, 12(21), pp. 1–22. doi:10.3390/su12219194.
- Rehman, S. and Rehman, A. (2019) *Physiology, Coronary Circulation, StatPearls*. StatPearls Publishing.
- Reiss, A.B., Siegart, N.M. and de Leon, J. (2017) "Interleukin-6 in Atherosclerosis: Atherogenic or Atheroprotective?," *Clinical Lipidology*, 12(1), pp. 14–23. doi:10.1080/17584299.2017.1319787.
- Ridker, P.M. (2021) "Inhibiting Interleukin-6 to Reduce Cardiovascular Event Rates," *Journal of the American College of Cardiology*, 77(15). doi:10.1016/j.jacc.2021.02.060.
- Ridker, P.M. and Rane, M. (2021) "Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease," *Circulation Research*, 128(11). doi:10.1161/CIRCRESAHA.121.319077.
- Romeo, F. *et al.* (2014) "Guidelines on the management of stable coronary artery disease," *Acta Cardiologica*, 69(1), pp. 51–52. doi:10.2143/AC.69.1.3011345.
- Saladin, K.S., Gan, C.A. and Cushman, H.N. (2018) *Anatomy & Physiology: The Unity of Form and Function*. 8th edn. New York: McGraw Hill Education.
- Salimetrics (2017) *Salivary Il-6*.

- Santoso, A. (2017) "Kelainan Lipid dan Lipoprotein, serta Penyakit Kardiovaskular," in Yuniadi, Y., Hermanto, D.Y., and Siswanto, B.B. (eds) *Buku Ajar Kardiovaskular Jilid 2*. Jakarta: CV Sagung Seto.
- Scanlon, P.J. *et al.* (2012) "ACC/AHA Guidelines for Coronary Angiography: Executive Summary and Recommendations," *Circulation*, 99(17), pp. 2345–2357. doi:10.1161/01.cir.99.17.2345.
- Serruys, P.W. *et al.* (2009) "Assessment of the SYNTAX score in the Syntax study (EuroIntervention (2009) 5, (50-56))," *EuroIntervention*, 5(3), p. 401.
- Seyis, S., Gunay, S. and Rencuzoglu, I. (2017) "Relationship between platelet to lymphocyte ratio and coronary angiography timing in patients with NSTEMI," *Biomedical Research (India)*, 28(20), pp. 8963–8968.
- Shah, A.D. *et al.* (2015) "Type 2 Diabetes and Incidence of Cardiovascular Diseases: A Cohort Study in 1.9 Million People," *The Lancet Diabetes & Endocrinology*, 3(2), pp. 105–113. doi:10.1016/S2213-8587(14)70219-0.
- Sianos, G., Morel, M. and Kappetein, A.P. (2005) "The SYNTAX Score: an angiographic tool grading," (June 2014).
- Sobotta, J. (2010) *Sobotta Atlas Anatomi Manusia: Organ-Organ Dalam*. 23rd edn. Edited by F. Paulsen and J. Waschke. Jakarta: Penerbit Buku Kedokteran EGC.
- Soenarta, A.A. and Widyantoro, B. (2017) "Hipertensi Sistemik: Mekanisme, Diagnosis, dan Tata Laksana," in Yuniadi, Y., Hermanto, D.Y., and Siswanto, B.B. (eds) *Buku Ajar Kardiovaskular Jilid 2*. Jakarta: CV Sagung Seto.
- Sorsa, T. *et al.* (2010) "Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods," *Oral Diseases*, 16(1), pp. 39–45. doi:10.1111/j.1601-0825.2009.01603.x.
- Sterba, J.P. (1997) "Interleukin-6: Structure-Function Relationship."
- Sunu, I. (2017) "Biologi Vaskular Aterosklerosis," in Yuniadi, Y., Hermanto, D.Y., and Siswanto, B.B. (eds) *Buku Ajar Kardiovaskular Jilid 2*. Jakarta: CV Sagung Seto.
- Tabas, I. (2016) "2016 Russell Ross Memorial Lecture in Vascular Biology: Molecular-Cellular Mechanisms in The Progression of Atherosclerosis," *Arteriosclerosis, Thrombosis, and Vascular Biology Named Lecture Review*, 37(2), pp. 183–189. doi:10.1161/atvbaha.116.308036.
- Tanaka, M. *et al.* (2012) "Eosinophil count is positively correlated with coronary artery calcification," *Hypertension Research*, 35(3). doi:10.1038/hr.2011.191.
- Teo, K. *et al.* (2014) "Predicting Outcome in the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)," *JACC: Cardiovascular Interventions*, 7(2), pp. 195–201. doi:10.1016/j.jcin.2013.10.017.
- Thiriet, M., Delfour, M. and Garon, A. (2015) "Vascular Stenosis: An Introduction," in *PanVascular Medicine*. Berlin, Heidelberg: Springer Berlin Heidelberg. doi:10.1007/978-3-642-37078-6_32.

- Tyagi, N. *et al.* (2018) "Interleukin-10 Gene Polymorphism and Coronary Artery Disease - A Review," *World Journal of Pharmacy and Pharmaceutical Sciences*, 7(12), pp. 366–374. doi:10.20959/wjpps201812-12725.
- Uman, L.S. (2011) "Systematic Reviews and Meta-Analyses," *J Can Acad Child Adolesc Psychiatry*, 20(1), p. 57. Available at: www.cochrane.org.
- Uysal, H.B. *et al.* (2016) "Blood Count Parameters can Predict the Severity of Coronary Artery Disease," *Korean Journal of Internal Medicine*, 31(6), pp. 1093–1100. doi:10.3904/kjim.2015.199.
- Vakili, H. *et al.* (2019) "Background," pp. 2–5.
- Virkler, K. and Lednev, I.K. (2009) "Analysis of body fluids for forensic purposes: From laboratory testing to non-destructive rapid confirmatory identification at a crime scene," *Forensic Science International*, pp. 1–17. doi:10.1016/j.forsciint.2009.02.013.
- Wainstein, M. V. *et al.* (2017) "Elevated Serum Interleukin-6 is Predictive of Coronary Artery Disease in Intermediate Risk Overweight Patients Referred for Coronary Angiography," *Diabetology and Metabolic Syndrome*, 9(67), pp. 1–7. doi:10.1186/s13098-017-0266-5.
- Wainstein, M. v. *et al.* (2017) "Elevated Serum Interleukin-6 is Predictive of Coronary Artery Disease in Intermediate Risk Overweight Patients Referred for Coronary Angiography," *Diabetology and Metabolic Syndrome*, 9(1). doi:10.1186/s13098-017-0266-5.
- Walter, J. *et al.* (2018) "Clinical Utility of Circulating Interleukin-6 Concentrations in The Detection of Functionally Relevant Coronary Artery Disease," *International Journal of Cardiology*, 275, pp. 20–25. doi:10.1016/j.ijcard.2018.10.029.
- Wang, D. *et al.* (2017) "Roles of Cells from the Arterial Vessel Wall in Atherosclerosis," *Mediators of Inflammation*, 2017. doi:10.1155/2017/8135934.
- WHO (2000) "The Asia-Pacific Perspective: Redefining Obesity and It's Treatment.pdf." WHO.
- WHO (2017) *WHO | Cardiovascular diseases (CVDs)*, WHO. World Health Organization. Available at: [https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)) (Accessed: March 11, 2019).
- WHO (2019a) *CVD Atlas: Death from Coronary Heart Disease*.
- WHO (2019b) *CVD Atlas: Global Burden of Coronary Heart Disease*. Available at: https://www.who.int/cardiovascular_diseases/en/cvd_atlas_13_coronaryHD.pdf.
- WHO (2019c) *CVD Atlas: Risk Factor*. Available at: https://www.who.int/cardiovascular_diseases/en/cvd_atlas_03_risk_factors.pdf?ua=1.
- WHO (2019d) *CVD Atlas: Risk Factor: Diabetes*, WHO.
- Wicaksono, S.H. *et al.* (2017) "Panduan Interpretasi dan Pelaporan Angiografi Koroner dengan Tomografi Komputer," *Indonesian Journal of Cardiology*, pp. 107–16. doi:10.30701/ijc.v37i2.573.

- Winther, M.P.J. de *et al.* (2019) "Clinical Implications of Basic Research The Link between Hematopoiesis and Atherosclerosis," pp. 1869–1871.
- Winzer, E.B., Woitek, F. and Linke, A. (2018) "Physical activity in the prevention and treatment of coronary artery disease," *Journal of the American Heart Association*, 7(4), pp. 1–15. doi:10.1161/JAHA.117.007725.
- Wolf, D. and Ley, K. (2019) "Immunity and Inflammation in Atherosclerosis," *Circulation Research*, 124(2). doi:10.1161/CIRCRESAHA.118.313591.
- Wong, N.D. (2014) "Epidemiological Studies of CHD and The Evolution of Preventive Cardiology," *Nature Reviews Cardiology*, 11(5), pp. 276–289. doi:10.1038/nrcardio.2014.26.
- Wu, M.Y. *et al.* (2017) "New insights into the role of inflammation in the pathogenesis of atherosclerosis," *International Journal of Molecular Sciences*, 18(10). doi:10.3390/ijms18102034.
- Xiang, F. *et al.* (2018) "Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: A prospective cohort study," *Hemodialysis International*, 22(1). doi:10.1111/hdi.12549.
- Yang, Y. *et al.* (2020) "Predictive Efficacy of Neutrophil-to-Lymphocyte Ratio for Long-term Prognosis in New Onset Acute Coronary Syndrome: a Retrospective Cohort Study," *BMC Cardiovascular Disorders*, 20(1). doi:10.1186/s12872-020-01773-x.
- Zhou, D. *et al.* (2017) "Platelet to Lymphocyte Ratio is Associated with the Severity of Coronary Artery Disease and Clinical Outcomes of Percutaneous Coronary Intervention in the Chinese Han Population," *Experimental and Therapeutic Medicine*, 13(2), pp. 731–738. doi:10.3892/etm.2016.3993.

Tabel 17. Strategi Pencarian Literatur

Pencarian	Query	Jumlah Literatur
PUBMED		
#1	"Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome" Filters: in the last 5 years, Humans, English, Indonesian	33.437
#2	Stenosis OR (atherosclerosis OR atherosclerotic OR plaque) Filters: in the last 5 years, Humans, English, Indonesian	64.965
#3	Angiography Filters: in the last 5 years, Humans, English, Indonesian	41.072
#4	IL-6 OR interleukin-6 Filters: in the last 5 years, Humans, English, Indonesian	23.052
#5	Salivary OR saliva Filters: in the last 5 years, Humans, English, Indonesian	14.514
#6	Plasma OR serum Filters: in the last 5 years, Humans, English, Indonesian	176.581
#7	#1 AND #2 AND #3 AND #4 AND #6 Filters: in the last 5 years, Humans, English, Indonesian	0
#8	#1 AND #2 AND #3 AND #4 AND #5 Filters: in the last 5 years, Humans, English, Indonesian	20
#9	NLR OR "neutrophil/lymphocyte ratio" OR "neutrophil-lymphocyte ratio" OR "neutrophil-to-lymphocyte ratio" OR "neutrophil to lymphocyte ratio" OR "neutrophil lymphocyte ratio" Filters: in the last 5 years, Humans, English, Indonesian	5.980

#10	ELR OR "eosinophil-leukocyte ratio" OR "eosinophil/leukocyte ratio" OR "eosinophil-to-leukocyte ratio" OR "eosinophil to leukocyte ratio" OR "eosinophil leukocyte ratio" Filters: in the last 5 years, Humans, English, Indonesian	137
#11	MLR OR "monocyte/lymphocyte ratio" OR "monocyte-lymphocyte ratio" OR "monocyte -to-lymphocyte ratio" OR "monocyte to lymphocyte ratio" OR "monocyte lymphocyte ratio" Filters: in the last 5 years, Humans, English, Indonesian	714
#12	PLR OR "platelet/lymphocyte ratio" OR "platelet-lymphocyte ratio" OR "platelet-to-lymphocyte ratio" OR "platelet to lymphocyte ratio" OR "platelet lymphocyte ratio" Filters: in the last 5 years, Humans, English, Indonesian	1.779
#13	#1 AND #2 AND #3 AND (#9 OR #10 OR #11 OR #12) Filters: in the last 5 years, Humans, English, Indonesian	20
TRIP		
#1	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND (salivary OR saliva) AND (interleukin 6 OR IL 6) AND (Stenosis OR (atherosclerosis OR atherosclerotic OR plaque)) AND angiography from: 2016	28
#2	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND (serum OR plasma) AND (interleukin 6 OR IL 6) AND (Stenosis OR (atherosclerosis OR atherosclerotic OR plaque)) AND angiography from: 2016	228

#3	<p>“Coronary artery disease” OR “coronary heart disease” OR “acute coronary syndrome”) AND (Stenosis OR atherosclerosis OR atherosclerotic OR plaque)) AND angiography AND ((NLR OR “neutrophil/lymphocyte ratio” OR “neutrophil-lymphocyte ratio” OR “neutrophil-to-lymphocyte ratio” OR “neutrophil to lymphocyte ratio” OR “neutrophil lymphocyte ratio”) OR (ELR OR “eosinophil-leukocyte ratio” OR “eosinophil/leukocyte ratio” OR “eosinophil-to-leukocyte ratio” OR “eosinophil to leukocyte ratio” OR “eosinophil leukocyte ratio”) OR (MLR OR “monocyte/lymphocyte ratio” OR “monocyte-lymphocyte ratio” OR “monocyte -to-lymphocyte ratio” OR “monocyte to lymphocyte ratio” OR “monocyte lymphocyte ratio”) OR (PLR OR “platelet/lymphocyte ratio” OR “platelet-lymphocyte ratio” OR “platelet-to-lymphocyte ratio” OR “platelet to lymphocyte ratio”)) from: 2016</p>	18
COCHRANE		
#1	coronary artery disease OR coronary heart disease OR acute coronary syndrome	38.235
#2	stenosis	13.003
#3	angiography	16.434
#4	Interleukin 6	15.744
#5	saliva	7.909
#6	serum	108.144
#7	neutrophil lymphocyte ratio	632
#8	monocyte lymphocyte ratio	177
#9	platelet lymphocyte ratio	218
#10	eosinophil leukocyte ratio	52

#11	#1 AND #2 AND #3 AND #4 AND #5 from Jan 2016 to Jun 2021	0
#12	#1 AND #2 AND #3 AND #4 AND #6 from Jan 2016 to Jun 2021	1
#13	#1 AND #2 AND #3 AND #7 from Jan 2016 to Jun 2021	2
#14	#1 AND #2 AND #3 AND #8 from Jan 2016 to Jun 2021	1
#15	#1 AND #2 AND #3 AND #9 from Jan 2016 to Jun 2021	1
#16	#1 AND #2 AND #3 AND #10 from Jan 2016 to Jun 2021	0
GARUDA		
#1	Derajat stenosis koroner	5
#2	IL-6 angiografi	46
#3	angiografi koroner	27
EMERALD		
#1	(content-type:article) AND ("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome" AND (Stenosis OR (atherosclerosis OR atherosclerotic OR plaque)) AND ("Coroner Angiography" OR "coronary angiography") AND (IL-6 OR interleukin-6) AND (Salivary OR saliva))	23
#2	(content-type:article) AND ("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome" AND (Stenosis OR (atherosclerosis OR atherosclerotic OR plaque)) AND ("Coroner Angiography" OR "coronary angiography") AND (IL-6 OR interleukin-6) AND (Serum OR plasma))	23
#3	(content-type:article) AND ("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome" AND (Stenosis OR (atherosclerosis OR atherosclerotic OR	26

	plaque)) AND ("Coroner Angiography" OR "coronary angiography") AND (NLR OR "neutrophil/lymphocyte ratio" OR neutrophil-lymphocyte ratio OR "neutrophil-to-lymphocyte ratio" OR "neutrophil to lymphocyte ratio"))	
#4	"Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome" AND (Stenosis OR atherosclerosis OR atherosclerotic OR plaque)) AND ("Coroner Angiography" OR "coronary angiography") AND (ELR OR "eosinophil-leukocyte ratio" OR "eosinophil/leukocyte ratio" OR "eosinophil-to-leukocyte ratio" OR "eosinophil to leukocyte ratio")	33
#5	"Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome" AND (Stenosis OR atherosclerosis OR atherosclerotic OR plaque)) AND ("Coroner Angiography" OR "coronary angiography") AND (MLR OR "monocyte-lymphocyte ratio" OR "monocyte/lymphocyte ratio" OR "monocyte-to-lymphocyte ratio" OR monocyte to lymphocyte ratio)	36
#6	"Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome" AND (Stenosis OR atherosclerosis OR atherosclerotic OR plaque)) AND ("Coroner Angiography" OR "coronary angiography") AND (PLR OR "platelet-to-lymphocyte ratio" OR "platelet-lymphocyte ratio" OR "platelet/lymphocyte ratio" OR platelet to lymphocyte ratio)	33
BMJ		
#1	coronary (all words) in title and angiography (all words) in title or abstract and neutrophil monocyte lymphocyte platelet	2

	eosinophil (any words) in full text , from Jan 2016 to Jun 2021	
#2	coronary (all words) in title and angiography (all words) in title or abstract and interleukin (any words) in full text , from Jan 2016 to Jun 2021.	2
#3	coronary artery disease OR coronary heart disease OR acute coronary syndrome (any words) in title and angiography stenosis (any words) in title or abstract and interleukin lymphocyte monocyte eosinophil platelet neutrophil (any words) in full text , from Jan 2016 to Jun 2021.	10
HINDAWI		
#1	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND (Stenosis OR atherosclerosis OR atherosclerotic OR plaque)) AND ("Coroner Angiography" OR "coronary angiography") AND (IL-6 OR interleukin-6) AND (Salivary OR saliva)	2
#2	("coronary heart disease" OR "coronary artery disease" OR "acute coronary syndrome") AND (("interleukin 6" OR "IL 6" OR "IL 6" OR "interleukin 6") AND serum) AND stenosis AND angiography	10
#3	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND Stenosis AND angiography AND ((NLR OR "neutrophil-lymphocyte" OR "neutrophil lymphocyte" OR "neutrophil/lymphocyte ratio" OR "neutrophil-to-lymphocyte" OR "neutrophil to lymphocyte") OR (ELR OR "eosinophil leukocyte" OR "eosinophil-leukocyte" OR "eosinophil-to-leukocyte" OR	10

	"eosinophili to leukocyte" OR "eosinophili/leukocyte") OR (MLR OR "monocyte-lymphocyte" OR "monocyte lymphocyte" OR "monocyte to lymphocyte" OR "monocyte-to-lymphocyte" OR "monocyte/lymphocyte") OR (PLR OR "platelet to lymphocyte" OR "platelet lymphocyte" OR "platelet-to-lymphocyte" OR "platelet-lymphocyte" OR "platelet/lymphocyte"))	
IOS		
#1	(Semua Kolom:interleukin-6 OR Semua Kolom:IL-6 OR Semua Kolom:IL 6 OR Semua Kolom:interleukin 6) AND (Semua Kolom:angiography OR Semua Kolom:angiografi)	0
#2	(Semua Kolom:NLR OR Semua Kolom:neutrophil OR Semua Kolom:neutrofil) AND (Semua Kolom:angiography OR Semua Kolom:angiografi)	5
#3	(Semua Kolom:ELR OR Semua Kolom:eosinophil OR Semua Kolom:eosinofil OR Semua Kolom:MLR OR Semua Kolom:monocyte OR Semua Kolom:monosit OR Semua Kolom:PLR OR Semua Kolom:platelet) AND (Semua Kolom:angiography OR Semua Kolom:angiografi)	6
OPAC		
#1	angiografi OR angiography	12
#2	"interleukin-6" "IL-6"	9
#3	limfosit lymphocyte monosit monocyte platelet eosinofil eosinophili leukosit leukocyte angiografi angiography	78
NELITI		
#1	Angiografi	3
#2	Angiography	13

#3	Interleukin-6 IL-6	15
#4	Lymphocyte coronary	0
PROQUEST		
#1	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND (angiography) AND (stenosis) AND ("IL-6" OR "IL 6" OR "IL6" OR "interleukin 6" OR "interleukin-6") AND (saliva OR salivary)	91
#2	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND (angiography) AND (stenosis) AND ("IL-6" OR "IL 6" OR "IL6" OR "interleukin 6" OR "interleukin-6") AND (serum)	547
#3	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND Stenosis AND angiography AND ((NLR OR "neutrophil-lymphocyte" OR "neutrophil lymphocyte" OR "neutrophil/lymphocyte ratio" OR "neutrophil-to-lymphocyte" OR "neutrophil to lymphocyte") OR (ELR OR "eosinophil leukocyte" OR "eosinophil-leukocyte" OR "eosinophil-to-leukocyte" OR "eosinophil to leukocyte" OR "eosinophil/leukocyte") OR (MLR OR "monocyte-lymphocyte" OR "monocyte lymphocyte" OR "monocyte to lymphocyte" OR "monocyte-to-lymphocyte" OR "monocyte/lymphocyte") OR (PLR OR "platelet to lymphocyte" OR "platelet lymphocyte" OR "platelet-to-lymphocyte" OR "platelet-lymphocyte" OR "platelet/lymphocyte"))	258
NATURE		
#1	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND Stenosis AND	5

	angiography AND ((NLR OR "neutrophil-lymphocyte" OR "neutrophil lymphocyte" OR "neutrophil/lymphocyte ratio" OR "neutrophil-to-lymphocyte" OR "neutrophil to lymphocyte") OR (ELR OR "eosinophil leukocyte" OR "eosinophil-leukocyte" OR "eosinophil-to-leukocyte" OR "eosinophil to leukocyte" OR "eosinophil/leukocyte") OR (MLR OR "monocyte-lymphocyte" OR "monocyte lymphocyte" OR "monocyte to lymphocyte" OR "monocyte-to-lymphocyte" OR "monocyte/lymphocyte") OR (PLR OR "platelet to lymphocyte" OR "platelet lymphocyte" OR "platelet-to-lymphocyte" OR "platelet-lymphocyte" OR "platelet-lymphocyte" OR "platelet/lymphocyte"))	
#2	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND (angiography) AND (stenosis) AND ("IL-6" OR "IL 6" OR "IL6" OR "interleukin 6" OR "interleukin-6") AND (saliva OR salivary)	6
#3	("Coronary artery disease" OR "coronary heart disease" OR "acute coronary syndrome") AND (angiography) AND (stenosis) AND ("IL-6" OR "IL 6" OR "IL6" OR "interleukin 6" OR "interleukin-6") AND (serum OR plasma)	45
SAGE		
#1	[[All "coronary artery disease"] OR [All "coronary heart disease"] OR [All "acute coronary syndrome"]] AND [All stenosis] AND [All angiography] AND [All nlr] OR [All "neutrophil-lymphocyte"] OR [All "neutrophil lymphocyte"] OR [All "neutrophil/lymphocyte ratio"] OR [All "neutrophil-to-lymphocyte"] OR [All "neutrophil to lymphocyte"] OR [All elr] OR [All "eosinophil leukocyte"] OR [All "eosinophil-	19

	<p>leukocyte"] OR [All "eosinophil-to-leukocyte"] OR [All "eosinophil to leukocyte"] OR [All "eosinophil/leukocyte"] OR [All mlr] OR [All "monocyte-lymphocyte"] OR [All "monocyte lymphocyte"] OR [All "monocyte to lymphocyte"] OR [All "monocyte-to-lymphocyte"] OR [All "monocyte/lymphocyte"] OR [All plr] OR [All "platelet to lymphocyte"] OR [All "platelet lymphocyte"] OR [All "platelet-to-lymphocyte"] OR [All "platelet-lymphocyte"] OR [All "platelet/lymphocyte"]]</p>	
#2	<p>[[All "coronary artery disease"] OR [All "coronary heart disease"] OR [All "acute coronary syndrome"]] AND [All stenosis] AND [All angiography] AND [[All "interleukin-6"] OR [All "interleukin 6"] OR [All "interleukin6"] OR [All "il-6"] OR [All "il6"] OR [All "i l 6"]]</p>	20

Tabel 18. Skrining Eligibilitas Penelitian

No	Penulis	Judul	Alasan Eksklusi
1	Buljubasic, N. et al, 2017	Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography	<i>Inappropriate investigated test</i>
2	Sbrana, S. et al, 2020	Blood Monocyte Phenotype Fingerprint of Stable Coronary Artery Disease: A Cross-Sectional Substudy of SMARTool Clinical Trial	
3	Sivri, S. et al, 2019	Usefulness of white blood cell count to mean platelet volume ratio in the prediction of SYNTAX score in patients with non-ST elevation myocardial infarction	
4	Hu, Y. et al, 2019	Diagnostic value of circulating lncRNA ANRIL and its correlation with coronary artery disease parameters	<i>Inappropriate outcome</i>
5	Moradi, N. et al, 2018	Lower Expression of miR-10a in Coronary Artery Disease and its Association with Pro/AntiInflammatory Cytokines	
6	Gur, D.O. et al, 2018	The role of novel cytokines in inflammation: Defining peripheral artery disease among patients with coronary artery disease	
7	Fadaei, R. et al, 2020	Higher circulating levels of ANGPTL8 are associated with body mass index, triglycerides, and endothelial dysfunction in patients with coronary artery disease	
8	Al-Mohaissen, M.A. et al, 2016	A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity	
9	Zhang, T. et al, 2020	Relationship between monocyte/lymphocyte ratio and non-culprit plaque vulnerability in patients with acute coronary syndrome	
10	Wang, X. et al, 2017	Association of Platelet to lymphocyte ratio with non-culprit atherosclerotic plaque vulnerability in patients with acute coronary syndrome: an optical coherence tomography study	

11	Yang, L. et al, 2021	Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis
12	Sharma, K. et al, 2017	Is Neutrophil-to-Lymphocyte Ratio a Predictor of Coronary Artery Disease in Western Indians?
13	Rifhan, Z. et al, 2019	Hubungan Antara Neutrophyl-To-Lymphocyte Ratio dengan Jumlah Lesi Arteri Koroner Pada Pasien Sindroma Koroner Akut
14	Mahmood, Z. et al, 2020	The effect of acute exercise on interleukin-6 and hypothalamic–pituitary–adrenal axis responses in patients with coronary artery disease
15	Mitrokhin, V. et al, 2017	Association between interleukin-6/6R gene polymorphisms and coronary artery disease in Russian population: influence of interleukin-6/6R gene polymorphisms on inflammatory markers
16	Tajfard, M. et al, 2017	Serum concentrations of MCP-1 and IL-6 in combination predict the presence of coronary artery disease and mortality in subjects undergoing coronary angiography
17	Moradi, N. et al, 2018	Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease
18	Zhu, G.F. et al, 2019	Inflammation-Related MicroRNAs Are Associated with Plaque Stability Calculated by IVUS in Coronary Heart Disease Patients
19	Jehle, J. et al, 2019	Endocannabinoid 2-arachidonoylglycerol is elevated in the coronary circulation during acute coronary syndrome
20	Qoi, D.S.Q. et al, 2020	Detection of ADTRP in circulation and its role as a novel biomarker for coronary artery disease
21	Koçak, S. et al, 2016	Association of Severity of Coronary Lesion with Markers of Acute Infection and Inflammation in Patients with Acute Coronary Syndrome

22	Alfonso, A. et al, 2019	High Serum Cyclophilin C levels as a risk factor marker for Coronary Artery Disease
23	Wang, G. et al, 2018	Myeloperoxidase mediated HDL oxidation and HDL proteome changes do not contribute to dysfunctional HDL in Chinese subjects with coronary artery disease
24	Kim, J.H. et al, 2017	Total and differential WBC counts are related with coronary artery atherosclerosis and increase the risk for cardiovascular disease in Koreans
25	Gao, J. et al, 2020	Gut microbial taxa as potential predictive biomarkers for acute coronary syndrome and post-STEMI cardiovascular events
26	Fadaei, R. et al, 2020	Association of C1q/TNF-Related Protein-3 (CTRP3) and CTRP13 Serum Levels with Coronary Artery Disease in Subjects with and without Type 2 Diabetes Mellitus
27	Bouzidi, N. et al, 2017	Relationship of activin A levels with clinical presentation, extent, and severity of coronary artery disease
28	Wu, S. et al, 2020	MicroRNA-145 is involved in endothelial cell dysfunction and acts as a promising biomarker of acute coronary syndrome
29	Boyras, B. et al, 2018	Assessment of inflammatory parameters in obstructive coronary artery disease and cardiac syndrome X: an evolving value of neutrophil-lymphocyte ratio
30	Chittawar, S. et al, 2017	Neutrophil-lymphocyte ratio is a novel reliable predictor of nephropathy, retinopathy, and coronary artery disease in Indians with type-2 diabetes
31	Qiao, S. et al, 2020	Neutrophil–Lymphocyte Ratio (NLR) for Predicting Clinical Outcomes in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus: A Propensity Score Matching Analysis
32	Fan, Z. et al, 2018	Prognostic utility of the combination of monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with NSTEMI after primary

		percutaneous coronary intervention: a retrospective cohort study
33	Hong, D. et al, 2019	Prognostic implications of post-percutaneous coronary intervention neutrophil-to-lymphocyte ratio on infarct size and clinical outcomes in patients with acute myocardial infarction
34	Celik, A. et al, 2017	Red cell distribution width is correlated with extensive coronary artery disease in patients with diabetes mellitus
35	Luo, J.Y. et al, 2021	Association between MIF gene promoter rs755622 and susceptibility to coronary artery disease and inflammatory cytokines in the Chinese Han population
36	Yilmaz, M. et al, 2016	Could neutrophil/lymphocyte ratio be an indicator of coronary artery disease, coronary artery ectasia and coronary slow flow?
37	Wang, Z. et al, 2020	Correlation of neutrophil-to-lymphocyte ratio with the prognosis of non-ST-segment elevation in patients with acute coronary syndrome undergoing selective percutaneous coronary intervention
38	Shen, L. et al, 2019	Association of C1q/TNF-related protein-1 (CTRP1) serum levels with coronary artery disease



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu



JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari, M.Med.,Ph.D., Sp.CK. TELP. 081241850958, 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 76/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 27 Januari 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH19121106	No Sponsor Protokol	
Peneliti Utama	Andi Irhamnia Sakinah	Sponsor	
Judul Peneliti	IL-6 Saliva dan Profil Hematologi Sebagai Prediktor Derajat Stenosis Arteri Koroner Pada Penderita Penyakit Jantung Koroner		
No Versi Protokol	2	Tanggal Versi	22 Januari 2020
No Versi PSP	2	Tanggal Versi	22 Januari 2020
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo dan Laboratorium HUMRC Lt 6 RSUH Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 27 Januari 2020 sampai 27 Januari 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUII	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Tabel 19. Penilaian Risiko Bias Studi Kasus Kontrol

Penulis	Tahun	Selection				Comparability			Outcome		Total stars
		Is the case definition adequate? ²	Representativeness of cases	Selection of Controls	Definition of Controls	Comparability of cases and controls	Assessment of exposure	Same method of ascertainment for cases and controls	Non-response rate		
X-T Li	2020	A(★)	A(★)	B(0)	A(★)	A(★) B(0)	B(★)	A(★)	A(★)	A(★)	7
H Ji	2017	A(★)	A(★)	A(★)	A(★)	A(0) B(0)	B(★)	A(★)	A(★)	A(★)	7
HB Uysal	2016	A(★)	A(★)	A(★)	A(★)	A(★) B(0)	D(0)	A(★)	A(★)	A(★)	7

Tabel 20. Penilaian Risiko Bias Studi Potong Lintang dan Cohort

Penulis	Tahun	Representativeness of cohort	Selection		Ascertainment of exposure	Outcome of interest	Comparability of cohorts	Assessment of outcome	Adequate duration of follow up	Adequacy of follow up	Total stars
			of the non-exposed cohort	Selection of cohort							
<i>Cohort study</i>											
Y Yang	2020	B(★)	A(★)	A(★)	A(★)	B(0)	A(★) B(0)	A(★)	A(★)	D(0)	6
D Zhou	2017	B(★)	A(★)	AB(★)	A(★)	A(★)	A(★) B(★)	A(★)	A(★)	A(★)	9
<i>Cross-sectional</i>											
Muliana	2020	B(★)	A(★)	B(★)			A(★) B(0)	C(0)	A(★)		5
X Min	2017	B(★)	A(★)	A(★)			A(★) B(★)	A(★)	A(★)		7
N Kose	2019	B(★)	A(★)	A(★)			A(★) B(★)	A(★)	A(★)		7
H Haybar	2014	B(★)	A(★)	AB(★)			A(0) B(★)	A(★)	A(★)		6
M.V, Wainstein	2017	B(★)	A(★)	A(★)			A(★) B(0)	A(★)	A(★)		6

